Prestige Consumer Healthcare 2027 Q2 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Q2 revenue was $336.3 million, up 22.7% from $274.1 million in the prior year and down 1.6% excluding foreign currency and the Breathe Right and Liquorium acquisitions.
- The company said Q2 revenue growth reflected its first full quarter of ownership of Breathe Right and Liquorium, while organic revenue declined slightly due to Q1 order timing.
- First-half fiscal '27 revenue increased 70 basis points organically, with North America up 60 basis points and International up 110 basis points, excluding FX and acquisitions.
- First-half adjusted diluted EPS was $2.11, up approximately 5% from $2.02, and Q2 adjusted diluted EPS was $1.13, up approximately 6% versus the prior year.
- Q2 adjusted EBITDA grew double digits year over year, with an approximate 33% EBITDA margin; first-half adjusted gross margin was approximately 57%.
- First-half adjusted free cash flow was $123 million, down versus the prior year due entirely to working capital timing.
- Breathe Right and Liquorium acquisition revenue totaled $71 million to date, and management said both businesses were integrating rapidly and performing consistent with expectations.
- Base-business consumption trends were described as healthy, with strength in Dramamine, Ferretirs, Compound W, Hydralyte, and other GI brands.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, and thank you for standing by. Welcome to the second quarter 2027 Prestige Consumer Healthcare Inc. earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star one one again. Please be advised that this conference is being recorded. I would now like to hand the call over to your speaker today, Phil Terpolilli.
Please go ahead. Thanks, operator, and thank you to everyone who has joined today.
On the call with me are Ron Lombardi, our Chairman, President, and CEO, and Christine Sacco, our CFO and COO. On today's call, we will review our second quarter fiscal 2027 results, discuss our full-year outlook, and then take questions from analysts. A slide presentation accompanies today's call, and it can be accessed by visiting prestigeconsumerhealthcare.com, clicking on the Investors link, and then on today's webcast and presentation. Remember, some of the information contained in the presentation today includes non-GAAP financial measures. Reconciliations to the nearest GAAP financial measures are included in our earnings release and slide presentation. On today's call, management will make forward-looking statements around risks and uncertainties, which are detailed in the complete safe harbor disclosure on page two of the slide presentation that accompanies the call. These are important to review and contemplate.
Business environment uncertainty remains heightened due to supply chain constraints, high inflation, geopolitical events, which have numerous potential impacts. This means results could change at any time, and the forecasted impact of risk considerations is a best estimate based on the information available as of today's date. Additional information concerning risk factors and cautionary statements are available in our most recent SEC filings and most recent company 10-Q that was released this morning. I will now hand it over to our CEO, Ron Lombardi.
Ron? Thanks, Phil, and thanks to everyone for joining us today.
We are pleased to report that we exceeded sales and earnings expectations in the second quarter. Revenue grew nearly 23%, reflecting our first full quarter of ownership of both the Breathe Right and LaCorium acquisitions, which are off to a good start. As we expected, organic revenue declined slightly due to Q1 order timing. Total first-half organic growth was up approximately 1%, helped by strong base business consumption trends, led by continued strength in Dramamine, TheraTears, Compound W, and Hydralyte. The solid sales growth translated into strong profitability, with gross margins up as expected, thanks to both cost savings and accretion from the acquisitions. Adjusted EPS increased to $1.13, up approximately 6% versus the prior year. Adjusted free cash flow was down due to working capital timing, but our financial profile remains strong.
Now that we've funded the LaCorium acquisition, which closed on July 1st, we intend to use our strong free cash flow towards debt reduction through the balance of the fiscal year. With that, let's turn to slide five for an update on our acquisitions. Q2 was our first full quarter of ownership for the Breathe Right portfolio and the LaCorium Health acquisitions. One quarter in, we have delivered results consistent with our expectations and have confidence we have great long-term opportunities for each. Breathe Right is now the largest brand in our portfolio. It's a brand with strong heritage and accretive financial profile and an established presence in multiple geographies. The business was largely integrated in August, which now allows us to focus on a number of future opportunities, as shown on the page.
There is a large and growing opportunity in sleep by expanding with a broader consumer base seeking better quality sleep. Our future marketing efforts will build on the progress and marketing success Breathe Right targeted with this opportunity. In tandem, we're investing in adjacent opportunities, like the recent launch of Breathe Right Sports for better breathing during physical activity. Lastly, the business previously utilized numerous third parties across its operations. By leveraging our in-house resources, we see opportunities to accelerate innovation and distribution. Now for our acquisition in Australia, LaCorium Health. It's made up primarily of the Dermal Therapy brand, which represents over 70% of portfolio sales. It has a proven history with consumers in therapeutic skincare since the 1990s, built on need-state solution products. Currently, we are nearing the completion of major integration efforts, which we expect to be completed in November.
Over time, we also expect to realize additional synergies that should further enhance profitability. Similar to Breathe Right, LaCorium is also well-positioned for long-term brand building. Let's turn to slide six and review this in greater detail. As I just mentioned, Dermal Therapy is the vast majority of LaCorium sales, with the brand sold mainly in Australia and New Zealand. The brand stands for therapeutic skincare solutions across numerous categories, the largest of which are shown on the left side of the page. From lip care, which is Dermal Therapy's largest sales category, to acne, which is a small but fast-growing opportunity, the brand leverages its local heritage to drive success. These solutions have driven share results. In lip care, it's the clear number one category leader using unique ultra-moisturizing formulations superior to competition.
In foot care, Dermal Therapy holds a solid market position as a fast-growing player with solutions for dry, cracked heels and feet, and is recommended by doctors. Its product offerings also extend to other foot care needs like wart and nail fungus treatments. With this strong base, we anticipate future sales and market share growth in Australia. This is driven by two proven strategies that we expect to enhance and continue. First, we intend to leverage the brand's heritage as a highly efficacious needs-based solution with the "It Works" campaign. With a proven mix of influencer engagement and traditional advertising methods, we expect further opportunity for positive marketing impacts of this strategy. Second, the brand has a proven history of innovation. As an example, under its prior ownership, the brand extended into new categories by seeking unique formulations that can truly be additive in the marketplace.
Dermal Therapy's cold sore lysine gel is an excellent example of this, as it brought a unique combination of ingredients to combat all stages of a cold sore, not just treatment or healing individually. In summary, Dermal Therapy has a history of success in Australia, offering proven solutions across skincare for consumers and growing its market share over time. By continuing to execute proven brand-building tactics, we are well-positioned to continue rapid growth. Now, let's turn to slide seven for an update on eCommerce. A component of our successful marketing tactics is investment in the channels where consumers are shopping the most. The fastest-growing channel by a wide margin remains eCommerce, with a strong first-half performance further driven by consumers seeking value in an inflationary environment.
Our eCommerce business, led by Amazon and Walmart, continues to deliver consistent mid-teens consumption growth and market share gains for many of our leading brands, thanks to the impact of our long-term investments. As shown on the right-hand side of the page, we continue to make strategic investments to make sure we are driving long-term sustainable success. First, we are continually refining our content by individual brand to help drive consumer engagement and conversion, both directly through websites and through generative search. Second, we are making digital media investments with our partners, which can help drive returns across all retail channels. Third, we are optimizing and leading banner events for each of our retail partners, identifying the highest return and most relevant opportunities for our needs-based portfolio. Finally, we are doing this in a strategic way, ensuring we are profit-agnostic by channel wherever consumers decide to shop.
In summary, we are focused on consumer takeaway, have a history of success, and have put the capabilities in place for sustained growth moving forward. With that, I'll turn the call over to Chris to review the financials.
Thanks, Ron. Good morning, everyone. Let's turn to slide nine and review our second quarter fiscal 2027 financial results. As a reminder, the information in today's presentation includes certain non-GAAP information that is reconciled to the closest GAAP measure in our earnings release. Q2 revenue of $336.3 million grew 22.7% from $274.1 million in the prior year, and declined 1.6% excluding the effects of foreign currency and the acquisitions of the Breathe Right and LaCorium portfolios. The revenue change was expected, resulting from favorable Q1 organic revenue order timing and the first full quarter of ownership for both acquisitions. Adjusted EBITDA grew double digits versus prior year, and we delivered an approximate 33% EBITDA margin, consistent with our long-term expectation in the low to mid-30s. Adjusted diluted EPS increased approximately 6% versus the prior year, as the profit increase was partially offset by higher interest expense from the acquisitions.
Let's turn to slide 10 and discuss consolidated results for the first six months. For the first six months of fiscal 2027, revenues increased 70 basis points organically versus the prior year. By segment, excluding FX and acquisitions, North America segment revenues increased 60 basis points, and international segment revenues increased 110 basis points versus the prior year. In North America, many of our GI brands continue to experience growth. This includes Dramamine and its new marketing tactics implemented over the last year related to support for GLP-1 users who face nausea as the number one side effect of GLP-1 use. We also experienced strong growth in TheraTears related to continued category growth, along with Compound W, which is experiencing success in its new skin tag product that extends the brand into an adjacent category.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
9 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
